Plain Language Summary {#Sec1}
======================

Osteoarthritis is a common chronic condition that results from the breakdown of cartilage within the joint, leading to pain, swelling, and joint stiffness. There are no drugs that can prevent or cure osteoarthritis, but treatments are available to reduce osteoarthritis pain, including acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, viscosupplementation, and steroid injections. Steroid injection into the affected joint of a patient with knee osteoarthritis has been shown to reduce pain; however, because of the rapid outflow of drug from the joint, only short-term pain relief is achieved. A long-acting form of steroid that releases the active treatment slowly over time from a biodegradable bead has been shown to be effective in knee osteoarthritis. Compared with a short-acting steroid treatment, this extended-release formulation results in a longer presence of active steroid in the joint following injection. This extended-release steroid has also produced improved pain relief compared with a saline-placebo injection and a short-acting steroid injection as measured by patient-reported pain scales. Another way to measure the impact of treatment on osteoarthritis pain is to monitor the use of "rescue" medication provided to participants receiving treatment during trials in case they need to manage uncontrolled index-knee pain. In the current analysis, the extended-release steroid injection reduced the need for such rescue medication, compared with both saline-placebo and a short-acting steroid injection. Reduced use of rescue medication can indicate improved pain relief and can also limit patient use of secondary medications that may have harmful side effects.

Introduction {#Sec2}
============

Osteoarthritis of the knee (OAK) is a painful condition that contributes to reduced mobility and impaired quality of life \[[@CR1], [@CR2]\]. Symptomatic OAK is typically managed with analgesics, including oral agents \[e.g., acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids\] and standard intra-articular corticosteroid (IACS) injections \[[@CR2]--[@CR4]\]. Although oral pain-relieving agents can be effective in alleviating OAK pain, a number of associated adverse effects limit their long-term use \[[@CR2], [@CR4]--[@CR7]\]. Conventional IACS injections reduce pain and improve function in OAK; however, the analgesic effect of standard IACS, such as triamcinolone acetonide crystalline suspension (TAcs), may be of limited duration because of the rapid egress of corticosteroid from the joint space following injection \[[@CR8]--[@CR10]\]. Longer-acting IA pain relief treatments that reduce the long-term use of oral analgesics are needed for the management of patients with chronic OAK pain.

Triamcinolone acetonide extended-release (TA-ER) is a microsphere-enabled \[75:25 poly(lactic-co-glycolic acid), nominal drug load of 25% (w/w)\] longer-acting IA agent. Pharmacokinetic data show that TA joint residency time increased and systemic exposure decreased following TA-ER injection compared with standard TAcs in patients with OAK \[[@CR10]\]. This reduced systemic release of TA following TA-ER has been observed in several studies and may contribute to the reduced glycemic control disruption observed with TA-ER compared with TAcs treatment in patients with OAK and type 2 diabetes \[[@CR10]--[@CR13]\]. The local synovial fluid TA concentration profile following TA-ER injection is in line with the prolonged, clinically meaningful efficacy observed in randomized controlled trials of patients with OAK \[[@CR13]--[@CR15]\]. In a phase 3 study, TA-ER significantly improved mean average daily pain (ADP) intensity score compared with saline-placebo at the 12-week primary endpoint (*p *\< 0.0001) and provided continued significant improvements to week 16 (*p* \< 0.05) \[[@CR14]\]. TA-ER also provided significant improvements in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)-A (pain), -B (stiffness), and -C (function) and in the Knee Injury and Osteoarthritis Outcome Score-Quality of Life scores compared with both saline-placebo and TAcs at week 12 (*p *\< 0.05; prespecified exploratory endpoints) \[[@CR14]\]. In the same study, TA-ER demonstrated an acceptable safety profile and most adverse events (AEs) were grade 1 or 2 and nonserious \[[@CR14]\].

It is common in clinical trials of analgesic agents for rescue medication to be issued to participants for use as needed to manage uncontrolled index-knee pain \[[@CR16]\]. Measuring rescue medication use can provide important information on the robustness of the overall analgesic effect because effective pain medications should reduce the need for rescue medication. According to guidance from the US Food and Drug Administration, rescue medication can be used to define a "responder" in clinical studies and can be used as a primary outcome measure and, furthermore, rescue medication use should be considered a secondary endpoint when pain intensity is the primary efficacy endpoint \[[@CR17]\]. The use of rescue medication is frequently cited as a secondary endpoint or an additional efficacy measure in clinical trials evaluating the efficacy of other IA agents for OAK \[[@CR18]--[@CR23]\]. However, evidence is limited regarding the impact of conventional IACS on rescue medication use. One meta-analysis reported no difference in the proportion of rescue medication use with IA injection of conventional IACS \[[@CR18]\]. Conversely, in a phase 3 study of TA-ER, rescue medication (acetaminophen/paracetamol) was provided to patients to manage uncontrolled index-knee pain, and use was evaluated as an additional efficacy endpoint; significantly fewer rescue medication tablets were needed per week by patients treated with TA-ER than by those treated with saline-placebo through week 24 (*p* \< 0.05) \[[@CR14]\]. To better understand the impact of TA-ER treatment on the need for rescue medication across the TA-ER clinical program, we pooled available study data from three phase 2/3 studies and evaluated rescue medication use in patients with OAK.

Methods {#Sec3}
=======

Compliance with Ethics Guidelines {#Sec4}
---------------------------------

All procedures were conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Protocols of the three clinical studies (ClinicalTrials.gov identifiers: NCT01487161, NCT02116972, and NCT02357459) contributing information to the pooled analyses were approved by governing ethics bodies at the participating sites, and patients provided written informed consent before participating in any study-related procedures.

Study Design {#Sec5}
------------

Full details on patient eligibility, study design, and interventions in the phase 2 \[[@CR13]\], phase 2b \[[@CR15]\], and phase 3 \[[@CR14]\] clinical trials included in this pooled analysis have been reported and are briefly summarized here. All studies enrolled men and women ≥ 40 years of age whose body mass index was ≤ 40 kg/m^2^. Participants had symptomatic OAK as defined by American College of Rheumatology OA criteria for ≥ 6 months \[[@CR24]\], Kellgren--Lawrence grade 2/3 OA based on screening index-knee radiography \[[@CR25]\], and baseline ADP intensity score ≥ 5 to ≤ 9 (0--10 numeric rating scale) for ≥ 5 of the previous 7 days \[[@CR26], [@CR27]\]. Each trial used a similar multicenter, double-blind, randomized, parallel-group, controlled design. In each trial, patients were evaluated every 4 weeks following a single IA injection through 12 or 24 weeks. Data from patients treated with saline-placebo, TAcs 40 mg, and TA-ER 32 mg (delivered dose) were pooled for the purposes of this analysis.

Concomitant Medication {#Sec6}
----------------------

The following analgesics were considered restricted medications and were not to be taken or used during the studies: oral NSAIDs, aspirin (\> 325 mg/day), centrally acting pain medications (e.g., pregabalin, gabapentin, duloxetine, milnacipran), opioids, and topical therapies (e.g., topical NSAIDs, capsaicin, lidocaine patches, other local treatments) applied to the index knee. Rescue analgesic medication (acetaminophen/paracetamol 500-mg tablets) was issued to patients for use on an as-needed basis to manage uncontrolled index-knee pain or any other type of pain, and was not to be used for prophylaxis. Consumption of rescue medication was monitored through a daily diary reporting system, and pill counts were confirmed at the clinical site.

Study Assessments {#Sec7}
-----------------

The objective of the pooled analysis was to examine rescue medication use in three phase 2/3 clinical trials. Results from all three studies contributed to the findings for weeks 1--12 and results from the phase 2b/3 studies contributed to the findings from weeks 1--24. The mean number of rescue medication tablets used per week was computed for each patient by summing the number of tablets used in each weekly interval and dividing by the number of days of non-missing responses in the weekly interval.

Treatment-emergent AEs (TEAEs)---defined as any AE with onset after the administration of study treatment or any AE that was present at baseline but worsened in intensity through the end of the study---were analyzed.

Statistical Analysis {#Sec8}
--------------------

Effects of IA injection treatment on rescue medication use were measured by least-squares means (LSM) at each week through week 24 for TA-ER versus saline-placebo and TAcs, analyzed with mixed effects model for repeated-measures methodology on observed data with no imputation for missing data. Area under the effect (AUE) curves of rescue medication use for TA-ER versus saline-placebo and TAcs through week 12 (AUE~weeks1--12~) and week 24 (AUE~weeks1--24~) were analyzed using analysis of covariance, with study site as a covariate.

Results {#Sec9}
=======

Demographics and Baseline Disease Characteristics {#Sec10}
-------------------------------------------------

The pooled analysis included a total of 798 patients, with more patients receiving TA-ER (*N* = 324) than saline-placebo (*N* = 262) or TAcs (*N* = 212). Across the three studies, demographic and baseline disease characteristics were well balanced for the three treatment groups, including similar baseline ADP intensity scores (Table [1](#Tab1){ref-type="table"}). Most patients were female (58.6%) and white (84.3%). Mean body mass index at baseline was 30.55, 30.58, and 30.15 kg/m^2^, and OAK was Kellgren--Lawrence grade 3 in 60.8, 59.5, and 58.0% of patients in the TA-ER, saline-placebo, and TAcs treatment groups, respectively.Table 1Pooled demographic and baseline characteristicsTA-ER 32 mg\
*N* = 324Saline-placebo\
*N* = 262TAcs 40 mg\
*N* = 212Sex, *n* (%) Male139 (42.9)105 (40.1)86 (40.6) Female185 (57.1)157 (59.9)126 (59.4)Age, years, mean (SD)60.5 (9.16)61.4 (8.73)62.1 (10.06)Race, *n* (%) American Indian or Alaska Native01 (0.4)0 Asian23 (7.1)15 (5.7)18 (8.5) Black or African American26 (8.0)19 (7.3)13 (6.1) Native Hawaiian or other Pacific Islander4 (1.2)1 (0.4)2 (0.9) White269 (83.0)226 (86.3)178 (84.0) Other2 (0.6)01 (0.5)BMI (kg/m^2^), mean (SD)30.55 (4.771)30.58 (4.871)30.15 (4.864)BMI category, *n* (%) Normal (18.0--24.9 kg/m^2^)43 (13.3)32 (12.2)34 (16.0) Overweight (25.0--29.9 kg/m^2^)114 (35.2)91 (34.7)69 (32.5) Class I obese (30.0--34.9 kg/m^2^)100 (30.9)81 (30.9)72 (34.0) Class II obese (35.0--39.9 kg/m^2^)65 (20.1)57 (21.8)37 (17.5) Morbid obesity (≥ 40.0 kg/m^2^)2 (0.6)1 (0.4)0Years since primary diagnosis, mean (SD)7.10 (6.736)6.50 (5.781)7.35 (6.944)Kellgren--Lawrence grade, *n* (%) 2127 (39.2)106 (40.5)88 (41.5) 3197 (60.8)156 (59.5)123 (58.0) 4001 (0.5)Weekly average daily pain intensity score 5--5.9118 (36.4)99 (37.8)82 (38.7) 6--6.9107 (33.0)78 (29.8)70 (33.0) ≥ 799 (30.6)85 (32.4)60 (28.3)*BMI* body mass index, *SD* standard deviation, *TAcs* triamcinolone acetonide crystalline suspension, *TA*-*ER* triamcinolone acetonide extended-release

Rescue Medication Use {#Sec11}
---------------------

The use of rescue medication decreased following IA injection (Fig. [1](#Fig1){ref-type="fig"}a). The overall average number of rescue medication tablets used per day through 24 weeks \[LSM (standard error, SE)\] was 0.89 (0.090) for TA-ER compared with 1.32 (0.100) for saline-placebo, and the total LSM difference (95% CI) was − 0.43 (− 0.65, − 0.20; *p* = 0.0002) for TA-ER compared with saline-placebo (Fig. [1](#Fig1){ref-type="fig"}b). Fewer rescue medication tablets were used per week by patients treated with TA-ER than saline-placebo at all time points, and the decreased use was significant (*p* \< 0.05) at each of weeks 1--16 and 19--20 (Fig. [1](#Fig1){ref-type="fig"}a). Rescue medication use was also statistically significantly lower with TA-ER than with saline-placebo across weeks 1--12 (AUE~weeks1--12~; LSM difference, − 24.5; *p *= 0.0121) and weeks 1--24 (AUE~weeks1--24~; LSM difference, − 51.6; *p* = 0.0023; Table [2](#Tab2){ref-type="table"}).Fig. 1Rescue medication (acetaminophen/paracetamol 500-mg tablets) use following IA treatment. **a** Average rescue medication tablets used per day in each weekly interval. **b** Average rescue medication tablets used per day through 24 weeks. \**p* \< 0.05 versus saline-placebo. ^†^*p *\< 0.05 versus TAcs. *IA* intra-articular, *SE* standard error, *TAcs* triamcinolone acetonide crystalline suspension, *TA*-*ER* triamcinolone acetonide extended-releaseTable 2Area under the effect curve of average rescue medication useTA-ER 32 mg\
*N* = 324Saline-placebo\
*N* = 262TAcs 40 mg\
*N* = 212AUE~weeks1--12~ LSM (SE)82.6 (7.81)107.1 (8.57)103.7 (9.74) LSM difference vs. saline-placebo (*p* value)− 24.5 (0.0121) LSM difference vs. TAcs (*p* value)− 21.1 (0.0424)AUE~weeks1--24~ LSM (SE)135.6 (13.48)187.2 (14.80)167.9 (16.82) LSM difference vs. saline-placebo (*p* value)− 51.6 (0.0023) LSM difference vs. TAcs (*p* value)− 32.2 (0.0731)*AUE* area under the effect curve, *LSM* least-squares mean, *SE* standard error, *TAcs* triamcinolone acetonide crystalline suspension, *TA*-*ER* triamcinolone acetonide extended-release

The overall average rescue medication tablets used per day through 24 weeks was lower for TA-ER with an LSM (SE) of 0.89 (0.090) compared with 1.13 (0.113) for TAcs, and a total LSM difference (95% CI) through week 24 of − 0.24 (− 0.48, − 0.01; *p *= 0.0433) for TA-ER compared with TAcs (Fig. [1](#Fig1){ref-type="fig"}b). TA-ER treatment reduced rescue medication use compared with TAcs at each week through week 24, with the difference reaching significance (*p* \< 0.05) at weeks 6, 7, and 10 (Fig. [1](#Fig1){ref-type="fig"}a). TA-ER also significantly reduced rescue medication use across weeks 1--12 (AUE~weeks1--12~; LSM difference, − 21.1; *p *= 0.0424) and numerically reduced medication use across weeks 1--24 (AUE~weeks1--24~; LSM difference, − 32.2; *p* = 0.0731; Table [2](#Tab2){ref-type="table"}).

Safety {#Sec12}
------

Pooled safety data from the trials are presented in Table [3](#Tab3){ref-type="table"}. Most TEAEs were grade 1 or 2, and there were no deaths. The incidence of TEAEs (51.9, 49.2, and 56.1%, respectively) and serious TEAEs (3.1, 1.1, and 1.9%, respectively) was similar across the TA-ER, saline-placebo, and TAcs groups. Few patients discontinued because of TEAEs (1.2, 0.8, and 0.5% in the TA-ER, saline-placebo and TAcs groups, respectively).Table 3Summary of adverse eventsTA-ER 32 mg\
*N* = 324Saline-placebo\
*N* = 262TAcs 40 mg\
*N* = 212≥ 1 TEAE, *n* (%)168 (51.9)129 (49.2)119 (56.1) Grade 178 (24.1)51 (19.5)54 (25.5) Grade 277 (23.8)65 (24.8)59 (27.8) Grade 311 (3.4)13 (5.0)4 (1.9) Grade 42 (0.6)02 (0.9)≥ 1 serious TEAE10 (3.1)3 (1.1)4 (1.9)≥ 1 TEAE leading to study discontinuation4 (1.2)2 (0.8)1 (0.5)TEAE by maximum relationship Not related133 (41.0)108 (41.2)93 (43.9) Unlikely18 (5.6)13 (5.0)13 (6.1) Possibly, probably, or definitely related17 (5.2)8 (3.1)13 (6.1)≥ 1 index-knee TEAE53 (16.4)37 (14.1)22 (10.4)≥ 1 index-knee TEAE leading to study discontinuation3 (0.9)2 (0.8)1 (0.5)*TAcs* triamcinolone acetonide crystalline suspension, *TA*-*ER* triamcinolone acetonide extended-release, *TEAE* treatment-emergent adverse event

Discussion {#Sec13}
==========

In this pooled analysis of three phase 2/3 clinical trials, TA-ER provided pain relief as shown by significant and sustained reductions in rescue medication use from baseline. In addition, patients treated with TA-ER required less rescue medication throughout the studies than patients treated with saline-placebo or TAcs. The safety profiles of TA-ER, saline-placebo, and TAcs were similar in this pooled analysis and consistent with that in the individual studies.

Providing rescue medication to patients participating in OA clinical trials can prevent dropout due to episodes of acute breakthrough pain or lack of efficacy and can provide an alternative way of measuring pain relief across treatment arms. The use of rescue medication is a clinically important indicator of analgesic efficacy and can be a secondary or an exploratory outcome measure in OA studies \[[@CR16], [@CR17]\]. The current analysis adds to the efficacy profile of TA-ER by demonstrating a reduced need for secondary pain medication, which would potentially lower the cumulative exposure of a patient to the adverse effects of oral agents \[[@CR13], [@CR14]\].

The current analysis is limited by its pooled retrospective nature. This led to differences in the number of patients receiving each treatment because of differences in individual study designs and durations. In addition, the allowance to use rescue medication for any worsening pain, not limited to OA knee pain, may have confounded the results; however, given the fact that these were large randomized trials, the impact of this potential confounder was considered to be minimal.

Conclusions {#Sec14}
===========

In patients with painful OAK, TA-ER treatment reduced rescue medication use compared with saline-placebo and TAcs. These findings provide another indication of analgesic benefit of TA-ER beginning at week 1 and lasting throughout 24 weeks. Reducing concomitant analgesic medication use in this patient population may be an additional benefit of TA-ER treatment.
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